|
|
 |
Non-Executive Directors
Alan Kingsman, Chairman
Professor Alan Kingsman, age 58, is a co-founder of Oxford BioMedica and served as Chief Executive Officer from 1996 to 2008. He was appointed Chairman in July 2008. He is an internationally recognised authority on gene expression and retrovirus research and has over 25 years' experience in this field, including 17 years as co-director (with Susan Kingsman) of the Retrovirus Molecular Biology Group within the Biochemistry department of the University of Oxford. He continues to hold the title of Professor of Biochemistry at Oxford University and is a former fellow of St. Catherine’s College, Oxford. He has published extensively in the field and is named inventor on numerous patent applications and issued patents. He has acted as an advisor or consultant to UK research councils, World Health Organization (WHO) and a number of UK and international companies.
|
|
 |
|
Nick Rodgers, Deputy Chairman and Senior Independent Director
Nick Rodgers, age 50, was appointed to Oxford BioMedica's board in March 2004. He is a former investment banker with considerable experience in the life sciences sector. He is now chief executive of Ipso Ventures plc, an intellectual property commercialization business, having been head of life sciences and joint head of corporate finance at Evolution Beeson Gregory until December 2003. Nick joined Beeson Gregory in 1989 from accountants Ernst & Young, having also worked in the listing department of the London Stock Exchange. He is Chairman of Oxford BioMedica’s audit committee.
|
|
 |
|
Paul Blake, Non-Executive Director
Dr Paul Blake, aged 62, was appointed to Oxford BioMedica's board in January 2010. Dr. Blake has over 30 years international pharmaceutical/biotech experience, and is currently Senior Vice President and Chief Medical Officer of Æterna Zentaris Inc., a global biopharmaceutical company focused on oncology and endrocrine therapy. From 2001 to 2006, he held senior management positions at Cephalon Inc, including Executive Vice President, Worldwide Medical & Regulatory Operations from 2005. Dr Blake's previous positions include Senior Vice President and Medical Director, Clinical Research and Development at SmithKline Beecham Pharmaceuticals. He gained his medical degree from the London University, Royal Free Hospital.
|
|
 |
|
Alex Lewis, Non-Executive Director
Dr Alex Lewis, age 46, was appointed to Oxford BioMedica’s board in April 2008. Dr Lewis is an experienced consultant to the pharmaceutical and biotech industry with a background in medical research and drug development (24 years). Dr Lewis is Director, Transactions and Due Diligence at Datamonitor. Previously, he was head of the Partnering and Due Diligence practice of consultants Wood Mackenzie. Dr Lewis has been involved in the provision of Expert Reports and technical advice for the Initial Public Offerings (IPOs) and fundraising activities for biotech companies based in the US and Europe. He is Chairman of Oxford BioMedica’s remuneration committee.
|
|
 |
|
Andrew Heath, Non-Executive Director
Dr Andrew Heath, aged 60, was appointed to Oxford BioMedica's board in January 2010. Dr Heath is a healthcare and biopharmaceutical executive with in-depth knowledge of US and UK capital markets and international experience in marketing and sales, R & D and business development. He was Chief Executive Officer of Protherics plc from 1997 to 2008, taking the company from 30 to 350 staff and managing its eventual acquisition by BTG for £220 million. Prior to this, Dr Heath was President and Chief Executive Officer of Aerogen Inc, and previously held senior positions at Astra AB and Astra USA, including Vice President Marketing & Sales, and at Glaxo Sweden as Associate Medical Director. He is currently a non-executive director of XL TechGroup Inc, Anew Inc, Pioneer Technology Inc, and is a director of the BioIndustry Association.
|
|
 |
|
